SRNE.US Sorrento Therape

Healthcare Biotechnology USA Stocks
0.0003 USD
Close of Nov 18, 2026
Market cap
USD 165K
P/E
-
P/B
4.01x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is SRNE.US undervalued?

Graham number

The Graham number of Sorrento Therape cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sorrento Therape fundamental analysis

No fundamental analysis for Sorrento Therape yet.

Sorrento Therape stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sorrento Therape

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic t…

Full company profile